# To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

> **NCT03149211** · PHASE3 · WITHDRAWN · sponsor: **United BioPharma**

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** UB-421
- **DRUG:** current standard HAART treatment

## Key facts

- **NCT ID:** NCT03149211
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** project adjustment
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149211, "To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03149211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*